Superworth

Champions Oncology price to book ratio CSBR

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
16.9×
10-year median
20.2×
Against its 10-year history
32nd
percentile: 0 is its lowest day, 100 its highest
10-year range
5.5× to 198×
Peer median
1.9×

Champions Oncology's price to book ratio is 16.9× as of Oct 23, 2026.

That is below its ten-year median of 20.2×, lower than on 68% of days in the last ten years.

Over that time it ranged from 5.5× in Oct 2016 to 198× in Jan 2025.

The median for 10 healthcare stocks of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far16.9×16.8×24.3×
202523.2×14.6×198×
2024169×152×169×
202335.2×6.0×45.7×
20226.7×6.6×14.1×
202114.0×13.5×23.2×
202020.9×16.4×46.2×
201942.4×28.0×65.1×
201847.0×41.2×192×
2017114×10.3×157×
20168.7×5.1×94.4×
20157.6×5.7×10.8×
201485.3×13.4×107×

Against its peers

Companies in Healthcare nearest Champions Oncology's size, closest first, today.

CompanyPrice to book ratio
CSBRChampions Oncology16.9×
SPROSpero Therapeutics1.5×
LFVNLifevantage2.2×
APTAlpha Pro Tech0.9×
ATNMActinium Pharmaceuticals1.6×
ICCCImmucell3.0×
KEQUKewaunee Scientific1.3×
NEPHNephros3.2×
PDEXPro DEX4.2×
PLXProtalix BioTherapeutics2.9×
NATRNatures Sunshine Products1.3×
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Champions Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.